With Creatio's powerful low-code/no-code tools, both business and IT teams can automate operational and CRM workflows
BOSTON, Oct. 1, 2021 /PRNewswire-PRWeb/ — Creatio, a global software company that provides a leading no-code/low-code platform for process management and CRM, today announced it has been recognized in the September 2021 Gartner Magic Quadrant for Enterprise Low-Code Application Platforms (1).
The report evaluates 12 LCAP vendors, out of the hundreds that market their products as LCAPs, based on their Ability to Execute and Completeness of Vision. According to Gartner®, "Organizations are increasingly adopting LCAPs to enable fusion team development with IT and business to quickly deliver new solutions and modernize business capabilities." In their research they predict that "By 2025, 70% of new applications developed by enterprises will use low-code or no-code technologies, up from less than 25% in 2020."
Creatio believes this recognition is thanks to enterprise-ready flexible low-code capabilities that empower businesses from various industries to automate workflows faster than ever. With Creatio's powerful low-code/no-code tools both business and IT teams can automate operational and CRM workflows of any complexity and gain the freedom to own their automation.
"Low-code and no-code application development has become a real game-changer for many organizations worldwide. We are happy to see that the market matures, and we are inspired by how our customers leverage Creatio low-code platform to automate enterprise-grade workflows across thousands of use cases without touching the code," said Katherine Kostereva, CEO and Founder of Creatio. "It's an honor for us to be recognized by Gartner in their 2021 Magic Quadrant for Enterprise Low Code Application Platforms," she added.
Try Studio Creatio for free >>
(1) Gartner, Magic Quadrant for Enterprise Low-Code Application Platforms, Jason Wong, Kimihiko Iijima, Adrian Leow, Akash Jain, Paul Vincent, 20 September 2021. GARTNER and MAGIC QUADRANT are a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission
Disclaimer: Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Creatio
Creatio is a global software company providing a leading no-code/low-code platform for process management and CRM.
The company has been highly recognized as a market leader by key industry analysts. Its intelligent products accelerate sales, marketing, service and operations for mid-size and large enterprises. Together with hundreds of partners Creatio operates in 110 countries worldwide.
For more information, please visit http://www.creatio.com

Media Contact
Peter Moran, Indicate Media, (347) 880-2895, peter@indicatemedia.com
SOURCE Creatio
Fed Chair Powell, joined by Treasury Secretary Yellen, delivers his opening statement to the Senate Banking Committee, which touched on COVID, inflation, the labor market, and GDP growth.
On Nov. 15, institutional investors and hedge funds with at least $100 million in assets under management were required to file Form 13F with the Securities and Exchange Commission (SEC). With the latest round of 13Fs, one thing stands out: billionaires were buying stocks hand over fist. Billionaire Ken Griffin is a wildly successful investor who's known for extracting big wins from his firms' options positions.
Shares of biopharma company Vir Biotechnology (NASDAQ: VIR) are up 13.7% as of 11:57 a.m. ET on Monday in response to reports that a new strain of the COVID-19 virus has been identified. Indeed, headlines regarding the new omicron variant of the coronavirus began to surface before Thursday's Thanksgiving holiday. It just took a while for investors to connect the dots all the way back to Vir Biotechnology, which potentially benefits from a renewed outbreak of infections stemming from this new strain of the pandemic-causing virus.
Shares of cruise-line stocks are down again on Tuesday, with Carnival Corporation (NYSE: CCL) sliding 4.6% in 11 a.m. ET trading, and rivals Royal Caribbean (NYSE: RCL) and Norwegian Cruise Line Holdings (NYSE: NCLH) not far behind. As MarketWatch reports today, Moderna CEO Stéphane Bancel is warning that his company's Covid-19 vaccine may suffer "a material drop" in effectiveness at protecting patients from the new omicron variant of the SARS-CoV-2 coronavirus.
Those following along with Clover Health Investments, Corp. ( NASDAQ:CLOV ) will no doubt be intrigued by the recent…
Shares of Vir Biotechnology (NASDAQ: VIR) were soaring 18.5% as of 11:08 a.m. ET on Tuesday. The big gain came after H.C. Wainwright analyst Patrick Trucchio boosted his price target on Vir from $135 to $200. Several analysts are bullish about Vir's prospects.
Shares of Apple (NASDAQ: AAPL) stock closed up 2.2% on Monday following a holiday weekend that featured new commentary on the company and its products from Bloomberg. Last week, if you recall, Apple shares got a boost from reports that the company is planning to build an electric car with autonomous driving capability and also has an augmented reality headset in the works — one that will be powerful enough to work as a stand-alone device. Well, over the weekend, Bloomberg expanded on these reports, adding that Apple is also working to develop augmented reality (AR) glasses (i.e., something different from the headset) and predicting that consumers (and investors) might get their first look at the AR headset as early as June 2022 if the company decides to unveil it at Apple's planned Worldwide Developers Conference next June.
Yahoo Finance Live's Julie Hyman breaks down some of the leading national headlines.
Uranium stocks are finally in the news after several years, and you don't want to miss this opportunity.
As I was extolling the virtues of Social Security’s 5.9% COLA, the Centers for Medicare and Medicaid Services (CMS) announced that they were increasing the premium for Medicare Part B by 14.5%. As a reminder, Medicare is composed of two programs. Part A, Hospital Insurance (HI), which covers inpatient hospital services, skilled nursing facilities, home healthcare, and hospice care.
Ideally, your overall portfolio should beat the market average. But even the best stock picker will only win with some…
Adagio Therapeutics Inc. is riding high after the company said its experimental antibody is likely to be just as effective against the omicron variant of the coronavirus as it is against previous variants. The antibody, a drug called ADG20, affords protection for up to one year, according to the firm.
You only have a couple more days to profit in two different ways from tax-loss selling. From a statistical point of view, that means you’re finding a security whose gyrations can explain or predict at least half of the movements of your tax loss sale candidate.
Stock prices can go up and down for a number of reasons in the near term, but over many years, stocks tend to follow the underlying growth of the company. While Alibaba (NYSE: BABA) and Stitch Fix (NASDAQ: SFIX) have seen their share prices crater this year, both companies continue to post solid operating results. Here's why these growth stocks could be bargains at current prices.
A big weekend for advance box office sales and a new product offering were potential good news for believers in AMC's recovery.
The professor is known for being bullish on stocks, yet even he says trouble’s coming.
If you're a fan of stable healthcare companies that have the potential to pay you ever-rising dividends until the cows come home, Viatris (NASDAQ: VTRS) might well become a dream stock. The single most persuasive argument against it being too late to buy Viatris is that the company is just getting started. After all, its life as an independent entity started a mere year ago with the merger of Pfizer's generic drugs business, Upjohn, and Mylan.
CEO Satya Nadella sold about half his stake in the software company, according to recent filings with the Securities and Exchange Commission.
Fed Chairman Jerome Powell said Tuesday that the central bank could end its asset purchase program a few months sooner than currently planned, signaling confidence in the economic recovery despite jitters over the Omicron variant of the coronavirus.
Honeywell International (NASDAQ: HON) appears to be the next company in line for a breakup after its iconic peer, General Electric (NYSE: GE), announced plans to separate into three different companies over the next few years. The subject last received a highly vocal airing in 2017 when an activist hedge fund campaigned for Honeywell to spin off its aerospace business. The businesses would be valued higher by the market if management separated them than if they were still part of Honeywell.

source

Leave a Reply